Table 2.
Timeline of relevant activities potentially influencing utilisation of bisphosphonates in Australia (for further detail, see Peeters et al. [10])
| 2001 | PBS | Alendronate, risendronate, etidronate available for post-menopausal women with established osteoporosis with minimal trauma fracture |
| 2004 | ADRAC | Reports of eye-problems related to bisphosphonates |
| 2006 | ADRAC | Reports of osteonecrosis of the jaw related to bisphosphonates |
| 2007 | PBS | Bisphosphonates, also includes women > 70years with BMD T score < −3.0 |
| ADRAC | Reports of renal impairment related to bisphosphonates, particularly zolendronic acid. Further reports of osteonecrosis of the jaw related to bisphosphonates | |
| Media | ABC television - The 7.30 Report on osteonecrosis of the jaw related to alendronate | |
| TGA | Safety Alert -advice issued December 2007 about bisphosphonate drugs and osteonecrosis of the jaw | |
| 2008 | PBS | Zoledronic acid for patients with vertebral fracture |
| 2009 | PBS | Zolendronic acid, also includes women > 70years with BMD T score < −3.0 |